Mariner’s Lexicon Pharmaceuticals LXRX Stock Holding History

Mariner’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27K	Buy	11,239 +167	+2%	+$325	﹤0.01%	3464
2026 Q1	$17.3K	Buy	+11,072	New	+$16.1K	﹤0.01%	3498

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mariner's LXRX Position: Q2 2026 in Review

Mariner increased its Lexicon Pharmaceuticals (LXRX) stake by 1.5% in Q2 2026, buying an estimated $325 and bringing the position to 11,239 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #3464.

Mariner first reported a position in LXRX in Q1 2026 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

Mariner held 11,239 shares of Lexicon Pharmaceuticals worth $27K as of Q2 2026.
Mariner bought 167 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $325.
Lexicon Pharmaceuticals made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3464 holding.
Mariner first reported a position in Lexicon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.